AU2008299896B2 - Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety - Google Patents

Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety Download PDF

Info

Publication number
AU2008299896B2
AU2008299896B2 AU2008299896A AU2008299896A AU2008299896B2 AU 2008299896 B2 AU2008299896 B2 AU 2008299896B2 AU 2008299896 A AU2008299896 A AU 2008299896A AU 2008299896 A AU2008299896 A AU 2008299896A AU 2008299896 B2 AU2008299896 B2 AU 2008299896B2
Authority
AU
Australia
Prior art keywords
compound
composition
tartaric acid
mmol
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008299896A
Other languages
English (en)
Other versions
AU2008299896A1 (en
Inventor
Xiong Cai
Changgeng Qian
Haixiao Zhai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of AU2008299896A1 publication Critical patent/AU2008299896A1/en
Application granted granted Critical
Publication of AU2008299896B2 publication Critical patent/AU2008299896B2/en
Priority to AU2012202433A priority Critical patent/AU2012202433A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008299896A 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety Ceased AU2008299896B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202433A AU2012202433A1 (en) 2007-09-10 2012-04-27 Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
US60/971,056 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202433A Division AU2012202433A1 (en) 2007-09-10 2012-04-27 Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety

Publications (2)

Publication Number Publication Date
AU2008299896A1 AU2008299896A1 (en) 2009-03-19
AU2008299896B2 true AU2008299896B2 (en) 2012-02-02

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008299896A Ceased AU2008299896B2 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety

Country Status (7)

Country Link
US (3) US7846938B2 (enExample)
EP (1) EP2190287B1 (enExample)
JP (1) JP5474792B2 (enExample)
AU (1) AU2008299896B2 (enExample)
CA (1) CA2698944C (enExample)
ES (1) ES2526718T3 (enExample)
WO (1) WO2009035718A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662617C (en) 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
KR20170040798A (ko) * 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
US12630501B2 (en) 2019-09-08 2026-05-19 Hadasit Medical Research Services And Development Ltd. Anti-fibrotic compounds and use thereof
US12100049B2 (en) 2020-06-05 2024-09-24 Soltran, LLC Filtered POS processing of services
CN116710448B (zh) * 2021-01-20 2025-05-16 莱托克斯有限公司 被保护的hdac(组蛋白脱乙酰酶)抑制剂
US12530346B2 (en) 2021-12-24 2026-01-20 Solutran, LLC Data transmission filtering through a customized filter list

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
AU2007296744A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2124306C (en) * 1993-05-26 2004-04-06 Masami Muraoka Quinazolinone derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7572798B2 (en) 2001-02-26 2009-08-11 Mcgill University Combi-molecules having signal transduction inhibitory properties and DNA damaging properties
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
US20070027150A1 (en) 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
AU2007296745B2 (en) 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662617C (en) * 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
CA2667826C (en) 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
AU2007296744A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents

Also Published As

Publication number Publication date
EP2190287B1 (en) 2014-10-29
US20130338167A1 (en) 2013-12-19
HK1144532A1 (en) 2011-02-25
US7846938B2 (en) 2010-12-07
CA2698944C (en) 2015-06-16
CA2698944A1 (en) 2009-03-19
WO2009035718A1 (en) 2009-03-19
JP5474792B2 (ja) 2014-04-16
US20090076022A1 (en) 2009-03-19
EP2190287A1 (en) 2010-06-02
AU2008299896A1 (en) 2009-03-19
EP2190287A4 (en) 2012-07-25
US8846912B2 (en) 2014-09-30
ES2526718T3 (es) 2015-01-14
US20110053963A1 (en) 2011-03-03
JP2010539082A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
EP2190287B1 (en) Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
US8518910B2 (en) Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
US8455506B2 (en) Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662587C (en) Quinazoline based egfr inhibitors
US8349856B2 (en) Quinazoline based EGFR inhibitors
EP3111938B1 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2012202433A1 (en) Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
HK1144532B (en) Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
AU2012216752B2 (en) Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2012200462A1 (en) Quinazoline based EGFR inhibitors
AU2015200733A1 (en) Quinazoline based egfr inhibitors containing a zinc binding moiety

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired